Increased serum concentration of nerve growth factor in patients with microprolactinoma.
Nerve growth factor (NGF) is known to play a role as a circulating neurokine, integrating signals from the neuro-immuno-endocrine system. The ability of NGF to activate the pituitary-adrenocortical axis, together with the increase of its serum concentration in pregnancy and lactation, supports the hypothesis that NGF is secreted by the pituitary gland and plays a role as modulator of endocrine functions. Evidence obtained both in vitro and in vivo in experimental animal models suggests that lactotroph cells secrete both prolactin (PRL) and NGF. Furthermore, in previous studies we demonstrate that cell lines derived from dopamine (DA)-sensitive human prolactinomas express high levels of NGF messenger RNA and protein. On these basis, we studied serum NGF concentrations in female patients with microprolactinoma (n = 4) and in control women (n = 5). PRL and NGF were measured at the diagnosis, during the thyrotropin releasing hormone (TRH) test and after the therapy with DA D2 receptor agonist cabergoline (0.25 mg, twice a week). Results obtained suggested that hyperprolactinemia (70.3+/-8.4 ng/ml) paralleled markedly higher NGF levels (58.4+/-18.7 pg/ml) compared to controls (PRL 8.7+/-3.2 ng/ml, NGF 8.4+/-1.3 pg/ml). Serum concentrations of NGF and PRL during the TRH test were closely associated (r = 0.943, p < 0.01). Cabergoline therapy normalized PRL (7.9+/-3.6 ng/ml) and induced a significant decrease of NGF levels (12.5+/-4.9 pg/ml). In conclusions, data reported here indicated that, in human microprolactinomas, NGF is released in the bloodstream paralleling PRL-secretion and it is modulated by a neurotransmitter-regulated mechanism, since the normalization of PRL elicited by the DA D2 receptor agonist cabergoline induced a significant decrease of serum NGF as well.
Section of Pharmacology, Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, V. le Europa 11, Brescia 25123, Italy. sigala@med.unibs.it
Sandra
S
Sigala
Antonio
A
Martocchia
Cristina
C
Missale
Paolo
P
Falaschi
PierFranco
P
Spano
D000328:Adult; D000077465:Cabergoline; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D020932:Nerve Growth Factor / Q000097:blood*; D010911:Pituitary Neoplasms / Q000097:blood* / Q000188:drug therapy; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000097:blood* / Q000188:drug therapy; D013268:Stimulation, Chemical; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D018492:Dopamine Antagonists; D004873:Ergolines; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D020932:Nerve Growth Factor; D000077465:Cabergoline